title: Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation.
abstract: High serum concentration of low-density lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease. The efficacy of pantethine treatment on cardiovascular risk markers was investigated in a randomized, triple-blinded, placebo-controlled study, in a low to moderate cardiovascular disease (CVD) risk North American population eligible for statin therapy, using the National Cholesterol Education Program (NCEP) guidelines. A total of 32 subjects were randomized to pantethine (600 mg/day from weeks 1 to 8 and 900 mg/day from weeks 9 to 16) or placebo. Compared with placebo, the participants on pantethine showed a significant decrease in total cholesterol at 16 weeks (P=0.040) and LDL-C at 8 and 16 weeks (P=0.020 and P=0.006, respectively), and decreasing trends in non-high-density lipoprotein cholesterol at week 8 and week 12 (P=0.102 and P=0.145, respectively) that reached significance by week 16 (P=0.042). An 11% decrease in LDL-C from baseline was seen in participants on pantethine, at weeks 4, 8, 12, and 16, while participants on placebo showed a 3% increase at week 16. This decrease was significant between groups at weeks 8 (P=0.027) and 16 (P=0.010). The homocysteine levels for both groups did not change significantly from baseline to week 16. Coenzyme Q10 significantly increased from baseline to week 4 and remained elevated until week 16, in both the pantethine and placebo groups. After 16 weeks, the participants on placebo did not show significant improvement in any CVD risk end points. This study confirms that pantethine lowers cardiovascular risk markers in low to moderate CVD risk participants eligible for statins according to NCEP guidelines.
authors.affiliation: KGK Synergize Inc, London, ON, Canada.
authors.forename: Malkanthi
authors.initials: M
authors.lastname: Evans
authors.affiliation: The Princeton Longevity Center, Princeton, NJ, USA.
authors.forename: John A
authors.initials: JA
authors.lastname: Rumberger
authors.affiliation: Daiichi Fine Chemical Co, Ltd, Toyama, Japan.
authors.forename: Isao
authors.initials: I
authors.lastname: Azumano
authors.affiliation: Independent Consultant, Allentown, PA, USA.
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Napolitano
authors.affiliation: Kyowa Hakko USA, New York, NY, USA.
authors.forename: Danielle
authors.initials: D
authors.lastname: Citrolo
authors.affiliation: Kyowa Hakko USA, New York, NY, USA.
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Kamiya
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005431:Florida; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000178:diet therapy* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009864:Ontario; D010204:Pantetheine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D015415:Biomarkers; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010204:Pantetheine; C005425:pantethine; D002784:Cholesterol
keywords: cardiovascular diseases; controlled clinical trial; dietary supplements; hypercholesterolemia; nutritional and metabolic diseases; pantethine